www.ema.europa.eu

Syndicate content
Human medicines: pending European commission decisions and European public assessment reports (EPARs)
URL: http://www.ema.europa.eu
Updated: 2 years 24 weeks ago

Pending EC decision: Mektovi, binimetinib, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Braftovi, encorafenib, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Udenyca, pegfilgrastim, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Darzalex, daratumumab, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Slenyto, melatonin, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Pelgraz, pegfilgrastim, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Keytruda, pembrolizumab, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Pending EC decision: Yervoy, ipilimumab, Opinion date: 26-Jul-2018

Fri, 07/27/2018 - 13:00
Categories: Category 1

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Revision: 27, Authorised

Fri, 07/27/2018 - 10:13
Categories: Category 1

Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Revision: 27, Authorised

Thu, 07/26/2018 - 16:59
Categories: Category 1

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Revision: 19, Authorised

Thu, 07/26/2018 - 16:10
Categories: Category 1

Human medicines European public assessment report (EPAR): Extavia, interferon beta-1b, Revision: 20, Authorised

Thu, 07/26/2018 - 15:40
Categories: Category 1

Human medicines European public assessment report (EPAR): Giotrif, afatinib, Revision: 11, Authorised

Thu, 07/26/2018 - 15:25
Categories: Category 1

Human medicines European public assessment report (EPAR): Effentora, fentanyl, Revision: 20, Authorised

Thu, 07/26/2018 - 14:56
Categories: Category 1

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Revision: 6, Authorised

Thu, 07/26/2018 - 13:45
Categories: Category 1

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Revision: 6, Authorised

Thu, 07/26/2018 - 13:45
Categories: Category 1

Human medicines European public assessment report (EPAR): TachoSil, human fibrinogen / human thrombin, Revision: 22, Authorised

Thu, 07/26/2018 - 10:45
Categories: Category 1

Human medicines European public assessment report (EPAR): Humira, adalimumab, Revision: 67, Authorised

Thu, 07/26/2018 - 10:30
Categories: Category 1

Human medicines European public assessment report (EPAR): Daklinza, daclatasvir, Revision: 13, Authorised

Wed, 07/25/2018 - 16:15
Categories: Category 1
  • Professionalism.
    We are specialists in this field and like our activity, so we can guarantee the quality of our work.
  • Competitiveness.
    Individual solutions for a competitive price.
  • Confidentiality.
    We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership